<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(10)</volume><submitter>Zhong Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC.&lt;h4>Methods&lt;/h4>A retrospective study was conducted on 150 patients with advanced NSCLC who were treated with anlotinib and discontinued treatment after disease progression or intolerance due to adverse events. Progression-free survival (PFS) of advanced NSCLC patients served as an endpoint. Kaplan-Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients.&lt;h4>Results&lt;/h4>The median PFS of the whole 150-patient cohort was 5.0 months in (95% CI: 4.00-5.95), 5.0 months (95% CI: 3.0</pubmed_abstract><journal>Journal of thoracic disease</journal><pagination>6016-6022</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7656407</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.</pubmed_title><pmcid>PMC7656407</pmcid><pubmed_authors>Wei Q</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Zhong Y</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Tang X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.</name><description>&lt;h4>Background&lt;/h4>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC.&lt;h4>Methods&lt;/h4>A retrospective study was conducted on 150 patients with advanced NSCLC who were treated with anlotinib and discontinued treatment after disease progression or intolerance due to adverse events. Progression-free survival (PFS) of advanced NSCLC patients served as an endpoint. Kaplan-Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients.&lt;h4>Results&lt;/h4>The median PFS of the whole 150-patient cohort was 5.0 months in (95% CI: 4.00-5.95), 5.0 months (95% CI: 3.0</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Oct</publication><modification>2025-04-04T23:46:12.001Z</modification><creation>2025-04-04T23:46:12.001Z</creation></dates><accession>S-EPMC7656407</accession><cross_references><pubmed>33209434</pubmed><doi>10.21037/jtd-20-2855</doi></cross_references></HashMap>